The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Italy Edition: The Views of 103 Italian Patient Groups

The ‘Corporate Reputation of Pharma’ survey - the 2021 Ital edition is now in its 8th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 103 Italy-based patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups possess a unique understanding of the needs of the patients and represent their collated views. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. At the same time, many patient groups are also familiar with the complexities of pharma’s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve - all from a patient perspective.

2021’s 103 respondent Italian patient groups had, collectively, been in communication with 959,000 Italian patients during the year. 76% of the Italian patient groups responding to the 2021 ‘Corporate Reputation of Pharma’ survey worked or partnered with at least one pharma company that year. 

The report provides details on: 

• How the analyst measures pharma’s corporate reputation from a patient perspective; 
• The headline results of the 2021 Italy element of the ‘Corporate Reputation’ survey; 
• The companies included in the 2021 Italy analysis; and 
• The profiles of 2021’s respondent Italian patient groups. 

Companies assessed for corporate reputation in the 2021 Italy report 

AbbVie, AstraZeneca, Bayer, Biogen, Boehringer, Ingelheim, Bristol Myers Squibb, Chiesi Farmaceutici, Eli Lilly, Gilead Sciences, GSK, Janssen, Menarini, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Takeda and Teva 

COMPANY RANKINGS IN ITALY IN 2021 

• The top-three pharma companies in Italy in 2021, out of 22 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st - Novo Nordisk, 2nd - Pfizer, 3rd.
• The top-three pharma companies in Italy in 2021, out of 6 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st - Roche, 2nd - Novartis, 3rd. 
• The top-three ‘big-pharma’ companies in Italy in 2021, out of 12 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st - Pfizer, 2nd - GSK, 3rd. 
• The top-three ‘big-pharma’ companies in Italy in 2021, out of 5 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st - Roche, 2nd - Novartis, 3rd.